Shandong Boan Biotechnology Co., Ltd. (HKG: 6955)

Market Cap	4.91B
Revenue (ttm)	773.46M
Net Income (ttm)	66.41M
Shares Out	535.93M
EPS (ttm)	0.13
PE Ratio	70.32
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	123,000
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	8.73 - 24.20
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 27, 2024

About Shandong Boan Biotechnology

Shandong Boan Biotechnology Co., Ltd. develops, manufactures, and commercializes biologics in Mainland China and internationally. Its commercialized products include Boyounuo (BA1101) bevacizumab injection for the treatment of metastatic or recurrent non-small cell lung cancer (NSCLC), recurrent glioblastoma, epithelial ovarian, fallopian tube or primary peritoneal cancer, and cervical cancer; and Boyoubei BA6101, a human immunoglobulin G2 monoclonal antibody for the treatment of postmenopausal women with osteoporosis at high risk for fracture....

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 813
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6955

Financial Performance

In 2023, Shandong Boan Biotechnology's revenue was 618.13 million, an increase of 19.80% compared to the previous year's 515.96 million. Losses were -119.38 million, -64.02% less than in 2022.

Financial numbers in CNY